Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy Article Swipe
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1007/s10286-017-0432-8
· OA: W2656534723
When using droxidopa, what are the criteria to adjust the dosage, combine it with other medications, and define therapeutic success? Case presentationMrs. M is an 80-year-old woman with the parkinsonian variant of multiple system atrophy (MSA-P).She initially presented with a 3-year progressive history of imbalance and a slow gait.She reported frequent falls, a decline in the ability to complete activities of daily living (ADLs), and noted some uncontrollable jerkiness of her arms (not tremors).She later developed facial dyskinesia shortly after starting treatment with levodopa.She has been ambulatory with a walker and lives in an assisted living facility.Her past medical history is significant for hyperlipidemia, urinary urgency, occasional incontinence, and constipation.Her medications included atorvastatin 10 mg taken orally once daily (QD), oxybutynin 5 mg twice daily (BID), and docusate sodium 100 mg BID.Approximately 6 months ago, Mrs. M had several episodes of syncope, all occurring when she was rising from a seated to &
